Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy: Radiopharmaceutical Therapy

[131I]MIP-1375, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted therapy of prostate cancer (PCa)

Shawn Hillier, Ross Merkin, Kevin Maresca, Craig Zimmerman, John Barrett, Mathias Tesson, William Eckelman, Rob Mairs, John Joyal and John Babich
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 361;
Shawn Hillier
1Molecular Insight Pharmaceuticals, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ross Merkin
1Molecular Insight Pharmaceuticals, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Maresca
1Molecular Insight Pharmaceuticals, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Zimmerman
1Molecular Insight Pharmaceuticals, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Barrett
1Molecular Insight Pharmaceuticals, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathias Tesson
2Centre of Oncology and Applied Pharmacology, University of Glasgow, Glasgow, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Eckelman
1Molecular Insight Pharmaceuticals, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rob Mairs
2Centre of Oncology and Applied Pharmacology, University of Glasgow, Glasgow, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Joyal
1Molecular Insight Pharmaceuticals, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Babich
1Molecular Insight Pharmaceuticals, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 52 no. supplement 1 361

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online November 4, 2014.

Copyright & Usage 
© 2011

Author Information

  1. Shawn Hillier1,
  2. Ross Merkin1,
  3. Kevin Maresca1,
  4. Craig Zimmerman1,
  5. John Barrett1,
  6. Mathias Tesson2,
  7. William Eckelman1,
  8. Rob Mairs2,
  9. John Joyal1 and
  10. John Babich1
  1. 1Molecular Insight Pharmaceuticals, Cambridge, MA
  2. 2Centre of Oncology and Applied Pharmacology, University of Glasgow, Glasgow, United Kingdom

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: December 2014 to April 2025

AbstractFullPdf
Dec 2014200
Jan 2015100
Feb 2015100
Mar 2015200
Apr 2015200
May 2015200
Jun 20151000
Jul 2015600
Aug 2015300
Sep 2015400
Oct 2015300
Nov 2015500
Dec 2015600
Jan 2016700
Mar 2016300
Apr 2016800
Jun 2016500
Jul 2016400
Aug 20161200
Sep 2016100
Oct 20161000
Nov 201612500
Dec 2016200
Jan 2017100
Feb 2017200
Mar 2017400
May 2017300
Jun 2017700
Aug 2017100
Sep 2017300
Oct 2017100
Nov 2017200
Feb 2018100
Apr 20181000
May 2018200
Jun 2018100
Aug 2018100
Sep 2018700
Oct 2018200
Nov 2018100
Dec 2018300
Jan 2019100
Feb 2019300
Mar 2019100
Apr 2019300
May 2019300
Jun 20191400
Jul 2019500
Aug 2019500
Sep 2019500
Oct 2019100
Nov 2019500
Dec 2019300
Jan 2020600
Feb 20201300
Mar 20201800
Apr 20201900
May 20201100
Jun 20203900
Jul 20201400
Aug 20202700
Sep 20203300
Oct 20202000
Nov 20201900
Dec 20202600
Jan 2021800
Feb 20211200
Mar 2021900
Apr 20214800
May 2021800
Jun 2021500
Jul 20211500
Aug 20213100
Sep 2021900
Oct 20211200
Nov 20215500
Dec 20214000
Jan 20226100
Feb 20222000
Mar 20222900
Apr 20223500
May 20223200
Jun 2022300
Jul 20221100
Aug 2022900
Sep 2022300
Oct 2022300
Nov 2022200
Dec 2022300
Jan 2023600
Feb 2023200
Mar 2023300
Apr 2023300
May 20231100
Jun 2023500
Jul 2023700
Aug 20231100
Sep 2023900
Oct 20231000
Nov 2023900
Dec 20231000
Jan 20241200
Feb 2024800
Mar 2024400
Apr 20241200
May 2024900
Jun 20241000
Jul 2024600
Aug 2024400
Sep 2024200
Oct 2024600
Nov 2024200
Dec 2024300
Jan 2025100
Feb 2025500
Mar 2025600
Apr 20251500
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 52, Issue supplement 1
May 2011
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
[131I]MIP-1375, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted therapy of prostate cancer (PCa)
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
[131I]MIP-1375, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted therapy of prostate cancer (PCa)
Shawn Hillier, Ross Merkin, Kevin Maresca, Craig Zimmerman, John Barrett, Mathias Tesson, William Eckelman, Rob Mairs, John Joyal, John Babich
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 361;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
[131I]MIP-1375, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted therapy of prostate cancer (PCa)
Shawn Hillier, Ross Merkin, Kevin Maresca, Craig Zimmerman, John Barrett, Mathias Tesson, William Eckelman, Rob Mairs, John Joyal, John Babich
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 361;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy: Radiopharmaceutical Therapy

  • Urinary excretion of Yttrium-90 following intra-arterial microsphere treatment for liver tumours
  • Characterization of 177Lu-Affibody-HSA bioconjugate for radionuclide therapy of EGFR-expressing head and neck carcinomas
  • Low-dose hyper-radiosensitivity model for 131I radioimmunotherapy of non-Hodgkin’s lymphoma
Show more Oncology: Basic, Translational & Therapy: Radiopharmaceutical Therapy

Radiopharmaceutical Therapy II: Radioimmunotherapy

  • Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC)
  • Six of 12 relapsed/refractory indolent lymphoma patients treated 10 years ago with tositumomab and 131I-tositumomab remain in complete remission
  • Phase I clinical study of the feasibility of pretargeted radioimmunotherapy (PT-RAIT) in patients with colorectal cancer (CRC): First results
Show more Radiopharmaceutical Therapy II: Radioimmunotherapy

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire